Migraine Prevention with Erenumab: Focus on Patient Selection, Perspectives and Outcomes
Sign Up to like & getrecommendations! Published in 2022 at "Therapeutics and Clinical Risk Management"
DOI: 10.2147/tcrm.s263825
Abstract: Abstract Erenumab is a monoclonal antibody targeting the calcitonin gene-related peptide (CGRP) receptor suitable for episodic and chronic migraine prevention. Randomized clinical trials proved the superiority of erenumab to placebo in a strictly selected population,… read more here.
Keywords: prevention erenumab; erenumab focus; treatment; migraine prevention ... See more keywords